Braidwell LP Sells 184,960 Shares of Glaukos Co. (NYSE:GKOS)

Braidwell LP decreased its stake in shares of Glaukos Co. (NYSE:GKOS) by 37.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 311,616 shares of the medical instruments supplier’s stock after selling 184,960 shares during the period. Braidwell LP owned approximately 0.57% of Glaukos worth $40,597,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in GKOS. Values First Advisors Inc. acquired a new stake in Glaukos during the 3rd quarter worth approximately $25,000. Harvest Fund Management Co. Ltd grew its stake in shares of Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 860 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock worth $141,000 after acquiring an additional 486 shares in the last quarter. KBC Group NV grew its position in Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after buying an additional 201 shares during the period. Finally, Fifth Third Wealth Advisors LLC bought a new position in Glaukos during the second quarter valued at about $187,000. Institutional investors own 99.04% of the company’s stock.

Glaukos Price Performance

Shares of Glaukos stock opened at $142.69 on Friday. Glaukos Co. has a twelve month low of $59.58 and a twelve month high of $146.86. The business has a 50-day moving average price of $133.81 and a 200 day moving average price of $124.52. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The firm has a market cap of $7.87 billion, a PE ratio of -47.25 and a beta of 1.02.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20. The company had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. Glaukos’s quarterly revenue was up 23.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.50) EPS. Sell-side analysts predict that Glaukos Co. will post -1.91 earnings per share for the current fiscal year.

Insider Activity at Glaukos

In other news, COO Joseph E. Gilliam sold 2,275 shares of the stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the sale, the chief operating officer now owns 102,169 shares in the company, valued at approximately $14,198,425.93. This represents a 2.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gilbert H. Kliman sold 3,000 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the sale, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. The trade was a 8.49 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on GKOS shares. JPMorgan Chase & Co. increased their price target on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Needham & Company LLC raised their price target on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Truist Financial lifted their price target on Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Piper Sandler set a $140.00 price objective on Glaukos in a report on Thursday, October 17th. Finally, BTIG Research boosted their price target on Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Glaukos has an average rating of “Moderate Buy” and an average price target of $135.45.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.